SpinalCyte introduced a new company name, FibroGenesis, reflecting its intellectual property portfolio that includes a treatment for degenerative disc disease (DDD) and other chronic diseases.
The company’s CybroCell™ is reportedly the first off-the-shelf allogenic human dermal fibroblast product for the treatment of DDD. In Phase I/II clinical study, patients injected with CybroCell demonstrated sustained improvement in pain relief and increased back mobility.
CybroCell cells appear to be “immune neutral” to the recipient, allowing for more consistent quality across the platform and the ability to generate large quantities of cells to treat a greater number of patients. The company received FDA investigational new drug clearance for the next phase of clinical trials that will include tissue generation and non-opiod treatments for pain.
SpinalCyte introduced a new company name, FibroGenesis, reflecting its intellectual property portfolio that includes a treatment for degenerative disc disease (DDD) and other chronic diseases.
SpinalCyte introduced a new company name, FibroGenesis, reflecting its intellectual property portfolio that includes a treatment for degenerative disc disease (DDD) and other chronic diseases.
The company’s CybroCell™ is reportedly the first off-the-shelf allogenic human dermal fibroblast product for the treatment of DDD. In Phase I/II clinical study, patients injected with CybroCell demonstrated sustained improvement in pain relief and increased back mobility.
CybroCell cells appear to be “immune neutral” to the recipient, allowing for more consistent quality across the platform and the ability to generate large quantities of cells to treat a greater number of patients. The company received FDA investigational new drug clearance for the next phase of clinical trials that will include tissue generation and non-opiod treatments for pain.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
